SPOTLIGHT: Talabostat heads to Phase III


Point Therapeutics says it will push Talabostat for pancreatic cancer into Phase III after a mid-stage trial produced encouraging data. No unexpected toxicities were recorded in Phase II that would prevent advancement of the drug, says Point, which saw its stock jump on the news. Report